Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
A trial comparing alemtuzumab versus chlorambucil showed no survival advantage, but complete remissions were about 20% more frequent (as with fludarabine). Serious adverse effects are more frequent and varied.